Search CommunityWalk:


Northwest Biotherapeutics Inc

4800 Montgomery Lane
Suite 800
Bethesda, MD, USA

Category: Drug Delivery

Used in the following map:

Maryland Biotech Industry Map

Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. Its approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system.

Northwest Biotherapeutics has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company's technology platform, DCVax®, uses a patient's own dendritic cells, the starter engine of the immune system, which is loaded with tumor proteins or antigens. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. It combines a patient's own dendritic cells (DC) with cancer related proteins, or antigens, to induce immune responses against a patient's cancer cells.

Northwest Biotherapeutics' ProstaView(TM) is a monoclonal antibody-based technology for the in vivo diagnostic imaging of metastatic prostate cancer. ProstaView(TM) antibodies bind to a protein called Prostate Specific Membrane Antigen (PSMA) located on the outside of live prostate cancer cells. The company's three product candidates include: DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer; DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme and monoclonal antibodies to CXCR4 for the treatment of cancer. DCVax®-Prostate and DCVax®-Brain has the ability to significantly delay disease progression, in addition to prolonging patient survival, while maintaining an excellent quality of life. CXCR4 is a monoclonal antibody therapy that targets the functional chemokine receptor.

Northwest Biotherapeutics has alliances with Cognate BioServices, Inc. (formerly Cognate Therapeutics, Inc.), Dako Denmark A/S (formerly DakoCytomation A/S), Inc, Medarex Inc, National Institutes of Health, Protein Sciences Corporation, Synteract, Inc., The National Cancer Institute and The US Department of Health and Human Services.